133 related articles for article (PubMed ID: 38163969)
1. Presurgical Medical Treatment in Prolactinomas: Surgical Implications and Pathological Characteristics From 290 Cases.
Chen Z; Shou X; Ji L; Cheng H; Shen M; Ma Z; He W; Ye Z; Zhang Y; Qiao N; Zhang Q; Wang Y
J Clin Endocrinol Metab; 2024 May; 109(6):1433-1442. PubMed ID: 38163969
[TBL] [Abstract][Full Text] [Related]
2. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
[TBL] [Abstract][Full Text] [Related]
5. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
[TBL] [Abstract][Full Text] [Related]
6. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
7. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
8. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
9. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
10. Effect of dopaminergic drug treatment on surgical findings in prolactinomas.
Menucci M; QuiƱones-Hinojosa A; Burger P; Salvatori R
Pituitary; 2011 Mar; 14(1):68-74. PubMed ID: 20878243
[TBL] [Abstract][Full Text] [Related]
11. Non-surgical management of cystic prolactinomas.
Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.
Giese S; Nasi-Kordhishti I; Honegger J
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):163-171. PubMed ID: 33461233
[TBL] [Abstract][Full Text] [Related]
13. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
14. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
15. Surgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality.
Kim EH; Kim J; Ku CR; Lee EJ; Kim SH
Yonsei Med J; 2023 Aug; 64(8):489-496. PubMed ID: 37488700
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
17. Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients.
Ottenhausen M; Conrad J; Wolters LM; Ringel F
Neurosurg Rev; 2023 May; 46(1):128. PubMed ID: 37249700
[TBL] [Abstract][Full Text] [Related]
18. Giant Prolactinomas: Outcomes of Multimodal Treatments for 42 Cases with Long-Term Follow-Up.
Lv L; Hu Y; Yin S; Zhou P; Yang Y; Ma W; Zhang S; Wang X; Jiang S
Exp Clin Endocrinol Diabetes; 2019 May; 127(5):295-302. PubMed ID: 29940665
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic Endonasal Transsphenoidal Surgery for Patients with Prolactinomas: Indications and Outcomes.
Force BK; Staggers K; Sebastian S; Takashima M; Yoshor D; Samson SL
World Neurosurg; 2022 Dec; 168():e626-e635. PubMed ID: 36270592
[TBL] [Abstract][Full Text] [Related]
20. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.
Kreutzer J; Buslei R; Wallaschofski H; Hofmann B; Nimsky C; Fahlbusch R; Buchfelder M
Eur J Endocrinol; 2008 Jan; 158(1):11-8. PubMed ID: 18166812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]